The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: Results of an 11-year randomized study

Clinical Infectious Diseases

Volumn 45, Issue 6, 2007, Pages 715-722

  Spyridis, Nikos P ^a   Spyridis, Panayotis G ^a   Gelesme, Anna ^a   Sypsa, Vana ^a   Valianatou, Mina ^a   Metsou, Flora ^a   Gourgiotis, Dimitris ^a   Tsolia, Maria N ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID; RIFAMPICIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ENZYME BLOOD LEVEL; EPIGASTRIC PAIN; FEMALE; HUMAN; INFANT; LONG TERM CARE; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHOTOSENSITIVITY DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SHORT COURSE THERAPY; SIDE EFFECT; THORAX RADIOGRAPHY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS;

ADOLESCENT; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; ISONIAZID; MALE; PROSPECTIVE STUDIES; RIFAMPIN; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 34548507470     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520983     Document Type: Article

References (44)

1. Cohn DL. Treatment of latent tuberculosis infection: renewed opportunity for tuberculosis control. Clin Infect Dis 2000; 31:120-4.
2. American Academy of Pediatrics, Pediatric Tuberculosis Collaborative Group. Targeted tuberculin skin testing and treatment of latent tuberculosis infection in children and adolescents. Pediatrics 2004; 114:1175-201. Available at: http://www.pediatrics.org/cgi/content/full/114/4/S2/1175.
3. Sterling TR, Bethel J, Goldberg S, et al. The scope and impact of treatment of latent tuberculosis infection in the United States and Canada. Am J Respir Crit Care Med 2006; 173:927-31.
4. Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl Tuberc 1970; 26:28-106.
5. Hsu KH. Isoniazid in prevention and treatment of tuberculosis: a 20-year study of the effectiveness in children. JAMA 1974; 229: 528-33.
6. International Union Against Tuberculosis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow up in the IUAT trial. Bull WHO 1982; 60:555-64.
7. Comstock GW. How much isoniazid is needed for the prevention of tuberculosis among immunocompetent adults. Int J Tuberc Lung Dis 2000; 4:485-6.
8. Starke JR. Current chemotherapy for tuberculosis in children. Infect Dis Clin North Am 1992; 6:215-35.
9. World Health Organizaiton. Treatment of tuberculosis: guidelines for national programmes. 3rd ed. Geneva: World Health Organization, 1997.
10. Khan K, Muenning P, Behta M, Zivin JB. Global drug-resistant patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347:1850-9.
11. Falzon D, Infuso A, Ait-Belghiti F. In the European Union, TB patients from former Soviet countries have a high risk of multidrug resistance. Int J Tuberc Lung Dis 2006; 10:954-8.
12. Villarino MF, Ritzon R, Weismuller PC, et al. Rifampicin preventive therapy for tuberculosis infection: experience with 157 adolescents. Am J Respir Crit Care Med 1997; 155:1735-8.
13. Hong-Kong Chest Service, Tuberculosis Research Centre, Madras, British Medical Council. A double-blind placebo-controlled clinical trial of three antituberculosis chemoprophylaxis regimens in patients with silicosis in Hong-Kong. Am Rev Respir Dis 1992; 145:36-41.
14. Ormerod LP. Rifampicin and isoniazid prophylactic chemotherapy for tuberculosis. Arch Dis Child 1998; 78:169-71.
15. Joint Tuberculosis Committee of the British Thoracic Society. Control and prevention of tuberculosis in the United Kingdom: code of practice 2000. Thorax 2000; 55:887-901.
16. Van Zyl S, Marais B, Hesseling A, Gie R, Beyers N, Schaaf H. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006; 10:13-8.
17. Spyridis P, Maltezou HC, Hantzakos A, Scondras C, Kafetzis DA. Mycobacterial cervical lymphadenitis in children: clinical and laboratory factors of importance of differential diagnosis. Scand J Infect Dis 2001; 33:362-6.
18. Palanduz A, Gultekin D, Kayaalp N. Follow up of compliance with tuberculous treatment in children: monitoring by urine tests. Pediatr Pulmonol 2003; 36:55-7.
19. American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000; 161:1376-95.
20. Ena J, Vails V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40:670-6.
21. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT. Active tuberculosis after isoniazid chemoprophylaxis of Southeast Asian refugees. Am Rev Respir Dis 1986; 133:431-6.
22. Starke JR, Jacobs RE, Jereb J. Resurgence of tuberculosis in children. J Pediatr 1992; 120:839-55.
23. Khan EA, Starke JR. Diagnosis of tuberculosis in children: increased need for better methods. Emerg Infect Dis 1995; 1:115-23.
24. Edwards DJ, Kitetele F, Van Rie A. Agreement between clinical scoring systems used for the diagnosis of pediatric tuberculosis in the HIV era. Int J Tuberc Lung Dis 2007; 11:263-9.
25. Marais BJ, Gie RP, Schaaf HS, Donald PR, Beyers N, Starke J. Childhood pulmonary tuberculosis: old wisdom and new challenges. Am J Resp Crit Care Med 2006; 173:1078-90.
26. Delacourt C, Mani TM, Bonnerot V, et al. Computed tomography with normal chest radiograph in tuberculosis infection. Arch Dis Child 1993; 69:430-2.
27. Levesque J, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis 2004; 8:711-7.
28. Coly A, Morisky D. Predicting completion of treatment among foreign-born adolescents treated for latent tuberculosis infection in Los Angeles. Int J Tuberc Lung Dis 2004; 8:703-10.
29. van Zyl S, Marais BJ, Hesseling AC, Gie RP, Beyers N, Schaaf HS. Adherence to anti-tuberculosis chemoprophylaxis and treatment in children. Int J Tuberc Lung Dis 2006; 10:13-8.
30. Marais BJ, van Zyl S, Schaaf HS, van Aardt M, Gie RP, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community-based study. Arch Dis Child 2006; 91:762-5.
31. Menzies R, Rocher I, Vissandjee B. Factors associated with compliance in treatment of tuberculosis. Tuber Lung Dis 1993; 74:32-7.
32. Arif K, Ali S A, Amanullah S, Siddiqui I, Khan J A, Nayani P. Physician compliance with national tuberculosis treatment guidelines: a university hospital study. Int J Tuberc Lung Dis 1998; 2:225-30.
33. Brown P. Private doctors must improve their treatment of tuberculosis says WHO. BMJ 2002; 325:1320.
34. Rothe TB, Karrer W. Short-course therapy of pulmonary tuberculosis: doctor's compliance. Tuber Lung Dis 1996; 77:93-7.
35. Kanavaki S, Mantadakis E, Nikolaou S, et al. Resistance of Mycobacterium tuberculosis isolates in different populations in Greece during 1993-2002. Int J Tuberc Lung Dis 2006; 10:559-64.
36. Starke JR. Multidrug therapy for tuberculosis in children. Pediatr Infect Dis J 1990; 9:785-93.
37. Schaaf HS, Marais BJ, Hesseling AC, Gie RP, Beyers N, Donald PR. Childhood drug- resistant tuberculosis in the Western Cape Province of South Africa. Acta Paediatrica 2006; 95:523-8.
38. Cynamon MH, Zhang Y, Harpster T, Cheng S, DeStefano MS. High dose isoniazid therapy for isoniazid resistant murine Mycobacterium tuberculosis infection. Antimicrob Agents Chemother 1999; 43: 2922-4.
39. Schaaf HS, Victor TC, Engelke F, et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis 2007; 26: 203-5.
40. American Thoracic Society, Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 1994; 149:1359-74.
41. Kucers A, Bennet M. The use of antibiotics: a comprehensive review with clinical emphasis. Philadelphia: J.B. Lippincot, 1987.
42. Jasmer RM, Snyder DC, Chin DP, et al. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost effectiveness analysis. Am J Respir Crit Care Med 2000; 162: 1648-52.
43. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Scwartzman K. Treatment completion and costs of a randomized trial of rifampicin for 4 month versus isoniazid for 9 months. Am J Respir Crit Care Med 2004; 170:445-9.
44. Rose DN. Short-course prophylaxis against tuberculosis in HIV-infected persons: a decision and cost-effectiveness analysis. Ann Intern Med 1998; 129:779-86.